<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[116, 120] concurrent capecitabine and radiotherapy<br>[132, 137] capecitabine and oxaliplatin plus radiotherapy<br></td>
<td width=33%>
[17, 21] adjuvant concurrent chemoradiotherapy]<br>[58, 67] capecitabine-based postoperative chemoradiotherapy (CRT).<br>[81, 88] CRT of capecitabine with or without oxaliplatin<br>[116, 126] concurrent capecitabine and radiotherapy (Cap-CRT),<br>[132, 145] capecitabine and oxaliplatin plus radiotherapy (Cap-Oxa-CRT).<br></td>
<td width=33%>
[5, 6] polymorphism<br>[17, 21] adjuvant concurrent chemoradiotherapy]<br>[58, 68] capecitabine-based postoperative chemoradiotherapy (CRT).
<br>[80, 88] postoperative CRT of capecitabine with or without oxaliplatin<br>[116, 126] concurrent capecitabine and radiotherapy (Cap-CRT),<br>[132, 145] capecitabine and oxaliplatin plus radiotherapy (Cap-Oxa-CRT).<br>[381, 386] Cap-Oxa-CRT<br>[422, 425] Cap-CRT<br></td>
</tr>
